GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » Land And Improvements

GH Research (GH Research) Land And Improvements : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GH Research Land And Improvements?

GH Research's land and improvements for the quarter that ended in Mar. 2024 was $0.00 Mil.


GH Research Land And Improvements Historical Data

The historical data trend for GH Research's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research Land And Improvements Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Land And Improvements
- - - - -

GH Research Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GH Research Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


GH Research (GH Research) Business Description

Traded in Other Exchanges
Address
28 Baggot Street Lower, Dublin, IRL, D02 NX43
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Its focus is on developing novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.